In non-obese participants with T2DM, GLP-1 RAs reduced the risk of MACE versus placebo (RR [95% CI]: 0.88 [0.79–0.98]), whereas SGLT-2 inhibitors did not have a statistically significant effect versus placebo (RR [95% CI]: 0.90 [0.80–1.02]) (Fig. 4B). This evidence concerns the gene GCG and type 2 diabetes mellitus.